The ACER1 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population featuring disruption of the ACER1 gene in the human KYSE-30 esophageal squamous cell carcinoma line. This engineered loss-of-function model enables investigation of alkaline ceramidase 1 within a cancer-relevant epithelial context. The polyclonal format maintains population diversity while eliminating ACER1 expression, allowing comparative studies with wild-type controls. It is supplied as a versatile tool for gene expression, lipid metabolism, and functional assays.
The parental KYSE-30 line originated from a poorly differentiated esophageal squamous cell carcinoma and is a standard model for esophageal cancer research. It retains malignant epithelial features and genetic aberrations characteristic of this tumor type, making it suitable for studying oncogenic signaling, drug sensitivity, and tumor progression. The knockout of ACER1 in this background provides a defined system to examine sphingolipid-dependent processes without interference from endogenous ceramidase activity.
ACER1 encodes alkaline ceramidase 1, an endoplasmic reticulum enzyme that hydrolyzes ceramides to sphingosine and fatty acids, governing the ceramide?Csphingosine balance. Its activity is modulated by upstream regulators including p53, inflammatory cytokines, and calcium, while downstream targets encompass sphingosine-1-phosphate (S1P), ceramide, BCL2 family proteins, and caspases. Disruption of ACER1 alters the conversion of ceramide to sphingosine, thereby affecting S1P signaling through S1PR1 and apoptotic pathways mediated by BAX and BCL2. Key interacting species are ceramides, sphingosine, and S1P, with ceramide synthase and sphingosine kinase 1 as critical metabolic enzymes. This knockout thus serves to dissect the sphingolipid rheostat and its impact on cell fate decisions.
In KYSE-30 esophageal cancer cells, ablation of ACER1 perturbs ceramide?CS1P signaling, which may alter apoptotic thresholds and drug responses. This model can reveal how ceramide accumulation or attenuated S1P production modulates sensitivity to chemotherapeutics like cisplatin that engage mitochondrial apoptosis. It also enables study of S1P-driven migration and invasion, processes relevant to esophageal squamous cell carcinoma metastasis. Combining this gene knockout with a clinically representative cell line yields a powerful system for translational research on sphingolipid metabolism in esophageal tumorigenesis.
Researchers can employ these cells for sphingolipid profiling via lipidomics, ceramide quantification, and S1P ELISA, alongside apoptosis detection by Annexin V/PI flow cytometry. The model supports Western blotting and RT-qPCR analysis of BCL2 family members, caspases, and sphingolipid enzymes. Cell proliferation, migration, and drug sensitivity assays further facilitate functional characterization. For additional information, contact Ascent Research.
